Fast-Tracked Medication Could Treat COVID-19 by Midsummer

Because coronavirus patients can’t wait another day

Thursday, April 16, 2020

It’s a long and expensive process between a medication being developed and brought to market, but with a global pandemic claiming victims by the thousands daily just in the United States, the Food and Drug Administration might provide some flexibility to companies that could offer something promising against COVID-19. 

That could happen as early as summer with the anti-viral drug Vicromax. It’s being supported for imminent clinical testing by the Mayo Clinic as a  major step toward FDA approval—the drug already having completed two initial testing phases.  

While summer approval would be too late for many patients, Vicromax and drugs like it could prepare the nation for the next version of the coronavirus. 

“All the experts seem to agree this will be a seasonal issue,” says Andrew Filler, a patent lawyer who is aiding Connecticut-based BioSig Technologies Inc. in the drug’s development. “The government may want to stockpile this drug for the near future. The next season could be this fall. 

Legal details of approval

Well before the leaves turn color, Filler hopes to have helped BioSig’s subsidiary company, ViralClear, secure a foundational IP position for Vicromax as it commences clinical trials as early as next month.  

A board member as well as IP adviser to the company, Filler actually is general counsel of the California-based Sherpa Technology Group that aids corporate clients in assembling and monetizing a patent portfolio. BioSig being a Sherpa client, Filler helped it acquire the rights to Vicromax from Trek Therapeutics, a Cambridge, Massachusetts, company that lacked the infrastructure to further develop it.

“All the experts seem to agree this will be a seasonal issue. The government may want to stockpile this drug for the near future. The next season could be this fall.

Now, Filler says, there’s optimism that Vicromax could be used in combination with other drugs that together show effectiveness against COVID-19 and its inevitable mutations. 

Assessing the potential of this combo has been outsourced to one of BioSig’s majority-owned subsidiaries, NeuroClear Technologies Inc., noted for its innovations in bioelectronic medicine.   

“Stopping the COVID-19 pandemic and preventing similar viral threats in the future must be the number-one priority of all of us in the healthcare community,” BioSig Chairman and CEO Kenneth L. Londoner said in a recent statement. “This very promising anti-viral is the result of tireless efforts by an accomplished group of pharmaceutical industry veterans, and we are doing everything in our power to ensure it gets tested and brought to market as soon as possible. 

And that necessitates all hands on deck. 

Knowing IP 

Filler helped ready BioSig for this mission long before COVID-19 became a pandemic. Founded in 2009the company was big on innovation but short on patents. Filler brought in Sterne Kessler Goldstein and Fox, a leading patent firm in Washington D.C., and together they helped secure six patents and filed for more than 20 more on BioSig’s Pure EP™ System, positioning the company to attract partners such as the Mayo Clinic that now could make a big difference against the virus. 

Filler emphasizes that it’s more a question of whennot ifthe next coronavirus strikes.  

Over 200 versions of varying severity exist of that virus. Previous deadly outbreaks included SARS in 2003 and MERS in 2012, though the common flu also kills hundreds of thousands of immuno-compromised people each year. But he’s optimistic about BioSig finding an Achilles heel in coronavirus. 

“This drug has a broad spectrum that attacks the underlying mechanism of viral replication” Filler says of Vicromax. “It could potentially be used against all coronaviruses. It’s a very broad drug that also has adaptability in animals. Remember, a tiger got COVID-19.” 

That 4-year-old Malayan tiger, Bronx Zoo resident Nadia, had developed a dry cough, along with some other big cats, but is expected to recover.

For the latest stories on how the legal community is responding to COVID-19, please follow Vanguard’s dedicated LinkedIn page. The stories are hosted on Vanguard’s blog.


I was honored to be the subject of an article. I enjoy reading Vanguard articles and seeing how other attorneys got to their positions and see their jobs. It's also interesting to see how different law firms partner with the subjects of the articles.
– Henry Marquard, in-house counsel, Stanley Consultants Inc.
The piece highlighting my company, Bob Baker Enterprises, Inc., came out fabulous. Our company is in the new and used car sales and service industry. Everyone was great to work with and extremely professional. They produced a high-quality product and have provided expert assistance and guidance post-production of the article.
– Wade Poulson, General Counsel, Bob Baker Enterprises Inc.
As promised in advance, my feature in Vanguard has increased my visibility within the profession and prompted more than a few people I have not communicated with recently to reconnect. One of the Italian law firms I have used in the past is now in the process of interviewing me for an article on their website and tweeting out the feature story. Activity and the number of people connecting with me on LinkedIn has soared, which is great. The Vanguard writers and editorial staff were great to work with—highly professional and made the effort to make the experience both fun and rewarding (they were also respectful of the time pressures and demands all lawyers face). I was very pleased with the experience and the final outcome. Needless to say, I have been very pleased. All in all working with Vanguard has been a very positive experience which generated good publicity for both Shawcor and myself. My sincere thanks.
– Tim Hutzul, General Counsel, ShawCor Ltd.
It was a great honor to be featured in Vanguard Law. Working with every member of the team, from the initial interview with Erin Clark, through production with Victor Martins, writing the article with Taryn Plumb and creating the final content with Dave Gushee, was a true pleasure. Everyone was very professional, enthusiastic and supportive, and their creative approach and positive attitude clearly came through in the final product.
– Kevin C. Rakowski, Senior Vice President, Deputy General Counsel, Compliance with Radian Group Inc.


Summer I 2024



  • * We’ll never share your email or info with anyone.
  • This field is for validation purposes and should be left unchanged.